A single dose of exenatide had no effect on blood flow velocity in the middle cerebral artery in elderly healthy volunteers: Randomized, placebo-controlled, double-blind clinical trial.
cerebral blood flow
clinical trial
exenatide
glucagon-like peptide 1
healthy volunteers
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
03
2022
accepted:
04
07
2022
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
14
1
2023
Statut:
epublish
Résumé
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) are widely used for the treatment of type 2 diabetes, and recent studies indicate that they may be cardio- and neuroprotective. The safety and effect of a single dose of exenatide, a short-acting GLP-1RA, on cerebral and peripheral arterial function remain unknown. In this randomized, double-blind pilot trial, we assigned elderly healthy volunteers without diabetes and no previous history of stroke to receive a single dose of subcutaneous exenatide (5 μg) or placebo. Primary outcome was immediate changes over time in blood flow velocity of the middle cerebral arteries (V Healthy volunteers (13 women and 17 men) were included: (mean ± standard deviation) age: 62 ± 8 years; body weight: 79.6 ± 12.7 kg; V A single dose of exenatide did not change cerebral blood flow velocity or peripheral vessel function in elderly healthy volunteers. The medication was safe to use in persons without diabetes allowing us to investigate this drug further in search of the neuroprotective mechanisms. https://clinicaltrials.gov, Identifier NCT02838589.
Sections du résumé
Background and aims
UNASSIGNED
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) are widely used for the treatment of type 2 diabetes, and recent studies indicate that they may be cardio- and neuroprotective. The safety and effect of a single dose of exenatide, a short-acting GLP-1RA, on cerebral and peripheral arterial function remain unknown.
Methods
UNASSIGNED
In this randomized, double-blind pilot trial, we assigned elderly healthy volunteers without diabetes and no previous history of stroke to receive a single dose of subcutaneous exenatide (5 μg) or placebo. Primary outcome was immediate changes over time in blood flow velocity of the middle cerebral arteries (V
Results
UNASSIGNED
Healthy volunteers (13 women and 17 men) were included: (mean ± standard deviation) age: 62 ± 8 years; body weight: 79.6 ± 12.7 kg; V
Conclusion
UNASSIGNED
A single dose of exenatide did not change cerebral blood flow velocity or peripheral vessel function in elderly healthy volunteers. The medication was safe to use in persons without diabetes allowing us to investigate this drug further in search of the neuroprotective mechanisms.
Clinical Trial Registration
UNASSIGNED
https://clinicaltrials.gov, Identifier NCT02838589.
Identifiants
pubmed: 36636739
doi: 10.3389/fnagi.2022.899389
pmc: PMC9831269
doi:
Banques de données
ClinicalTrials.gov
['NCT02838589']
Types de publication
Journal Article
Langues
eng
Pagination
899389Informations de copyright
Copyright © 2022 Ölmestig, Marlet, Vilsbøll, Rungby, Rostrup, Lambertsen and Kruuse.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Brain. 2003 Jan;126(Pt 1):241-7
pubmed: 12477710
J Clin Endocrinol Metab. 2012 Jul;97(7):E1165-9
pubmed: 22544917
J Am Heart Assoc. 2018 Nov 20;7(22):e010321
pubmed: 30571482
Stroke. 2020 Feb;51(2):666-669
pubmed: 31813360
Lancet Diabetes Endocrinol. 2016 Jun;4(6):525-36
pubmed: 26876794
J Neurochem. 2015 Feb;132(4):369-72
pubmed: 25656781
J Cereb Blood Flow Metab. 2004 Dec;24(12):1352-8
pubmed: 15625409
Cell Metab. 2018 Apr 3;27(4):740-756
pubmed: 29617641
Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):559-569
pubmed: 29411931
Br J Pharmacol. 2012 Jul;166(5):1586-99
pubmed: 22519295
Stroke. 1989 Jan;20(1):1-3
pubmed: 2911822
Brain Commun. 2020 Feb 20;2(1):fcaa020
pubmed: 33033800
Stroke. 1997 Jun;28(6):1195-7
pubmed: 9183350
Curr Hypertens Rep. 2016 Feb;18(2):16
pubmed: 26803771
Br J Pharmacol. 2019 Feb;176(3):386-399
pubmed: 30403290
Front Neurol. 2017 May 03;8:178
pubmed: 28515707
Acta Neuropathol. 2019 May;137(5):693-714
pubmed: 30483945
Sci Rep. 2021 Sep 17;11(1):18522
pubmed: 34535716
Diabetes. 2015 Jul;64(7):2624-35
pubmed: 25720388
Postgrad Med J. 2020 Mar;96(1133):156-161
pubmed: 31801807
BMJ. 2012 Jan 10;344:d7771
pubmed: 22236411
J Cereb Blood Flow Metab. 2002 Sep;22(9):1124-31
pubmed: 12218418
J Cereb Blood Flow Metab. 2021 Jan;41(1):14-30
pubmed: 32954901
Diabetes. 2012 Apr;61(4):888-96
pubmed: 22357961
J Ayub Med Coll Abbottabad. 2014 Apr-Jun;26(2):111-4
pubmed: 25603656
Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E355-62
pubmed: 24302010
BMJ. 2020 Feb 13;368:l6983
pubmed: 32054610
Brain. 2018 Oct 1;141(10):2943-2951
pubmed: 30137217
Am Heart J. 2003 Jul;146(1):168-74
pubmed: 12851627
Expert Opin Pharmacother. 2017 Apr;18(6):555-571
pubmed: 28085521
Diabetes Obes Metab. 2013 Aug;15(8):737-49
pubmed: 23433305
Mediators Inflamm. 2016;2016:3094642
pubmed: 27110066
Pharmacol Res. 2015 Apr;94:26-33
pubmed: 25697548
Eur J Pharmacol. 2005 Oct 3;521(1-3):105-14
pubmed: 16182282
Peptides. 2018 Feb;100:101-107
pubmed: 29412810
Diabetes Res Clin Pract. 2015 Oct;110(1):26-37
pubmed: 26358202